Available Clinical Trials at Pacific Cancer Care
Pacific Cancer Care is driven by a vision to be the leader for the treatment of cancer in the Monterey County. Our clinicians and investigators identify and conduct Phase I-IV treatment options that are new and innovative, and that will positively impact our patients. Below is a list of clinical trials currently available at Pacific Cancer Care.
For more information regarding clinical trial opportunities, please contact us at (831) 375-4105.
Solid Tumor and Hematologic Malignancies
Protocol Number: Patient-centered Outcomes Research Institute Study – Stanford – 63775
Protocol Title: Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults with Cancer
More Information available at: https://clinicaltrials.gov/ct2/show/NCT05297734
Breast Cancer
Protocol Number: CELC-G-301
Protocol Title: Phase 3, Open-Label, Randomized, Study Comparing Gedatolisib Combined With Fulvestrant & With or Without Palbociclib to Standard-of-Care Therapies in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination w/Non-Steroidal Aromatase Inhibitor Therapy
More information available at: https://clinicaltrials.gov/ct2/show/NCT05501886
Protocol Number: EMBER-4
Protocol Title: EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With an Increased Risk of Recurrence
More information available at: https://clinicaltrials.gov/ct2/show/NCT05514054
Urothelial Cancer
Protocol Number: SGNDV-001
An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination with Pembrolizumab Versus Chemotherapy in Subjects with Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma that Expresses HER2 (IHC 1+ and Greater)
More information available at: https://classic.clinicaltrials.gov/ct2/show/NCT04879329
Hematologic Malignancies
Protocol Number: MK-4280-003
Protocol Title: A Phase 1/Phase 2 Clinical Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies
More information available at: https://clinicaltrials.gov/ct2/show/NCT03598608
